MedTech Dive September 27, 2021
Dive Brief:
- Medtech M&A, investment in R&D and venture capital backing all jumped over the past year, according to analysts at EY.
- Growth in R&D spending at pure-play medtechs rose to a level last seen before the 2007-2008 financial crisis. Medtech companies also struck more takeover deals and received more VC funding than in any other year tracked by EY.
- Buoyed by the big year, the analysts see opportunities for medtech companies to rethink their business models, for example by leveraging data and pushing for regulatory changes.
Dive Insight:
The future of parts of the medtech industry looked highly uncertain as hospitals began deferring elective procedures in response to the pandemic early in 2020. However, while the pandemic...
Today's Sponsors
Today's Sponsor